Pediatric Oncology

Top Story

FDA authorizes IMPACT test to rapidly identify cancer mutations

FDA authorizes IMPACT test to rapidly identify cancer mutations
November 15, 2017

The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to rapidly identify the presence of mutations in 468 genes.

The test — developed by Memorial Sloan Kettering Cancer Center — also identifies molecular changes in the genomic makeup of a patient’s tumor. These findings can help inform clinicians about how best to treat the cancer.

Loxo Oncology, Bayer announce partnership for targeted cancer therapies

November 14, 2017
Loxo Oncology and Bayer have entered into a global partnership to develop and commercialize two targeted cancer therapies. The partnership is for larotrectinib…
In the Journals Plus

Childhood cancer survivors more likely to stay at jobs for health insurance

November 13, 2017
Job lock — the tendency to stay at a job in order to keep employer-provided health insurance — is common among childhood cancer survivors and may impact
FDA News

FDA approves dasatinib for children with Philadelphia chromosome-positive chronic myeloid leukemia

November 10, 2017
The FDA expanded the indication for dasatinib to include the treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic
More Headlines »
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video

Baseball Hall of Famer Mike Schmidt promotes sun protection, skin cancer awareness

September 28, 2017
More »
Resource Centers

CME ABIM MOC

Ace the Case: A 54-Year-Old Man With Intermittent, Painless Hematuria for the Past 4 Weeks

There is no commercial support for this activity.

This “Ace the Case” study will discuss the treatment of a 54-year-old man who presents with intermittent…
More »